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Protocol
AbstrAct
Introduction Exercise may positively alter tumour biology 
through numerous modulatory and regulatory mechanisms 
in response to a variety of modes and dosages, evidenced 
in preclinical models to date. Specifically, localised and 
systemic biochemical alterations produced during and 
following exercise may suppress tumour formation, 
growth and distribution by virtue of altered epigenetics 
and endocrine–paracrine activity. Given the impressive 
ability of targeted mechanical loading to interfere with 
metastasis-driven tumour formation in human osteolytic 
tumour cells, it is of equal interest to determine whether 
a similar effect is observed in sclerotic tumour cells. The 
study aims to (1) establish the feasibility and safety of a 
combined modular multimodal exercise programme with 
spinal isometric training in advanced prostate cancer 
patients with sclerotic bone metastases and (2) examine 
whether targeted and supervised exercise can suppress 
sclerotic tumour growth and activity in spinal metastases 
in humans.
Methods and analysis A single-blinded, two-armed, 
randomised, controlled and explorative phase I clinical 
trial combining spinal isometric training with a modular 
multimodal exercise programme in 40 men with advanced 
prostate cancer and stable sclerotic spinal metastases. 
Participants will be randomly assigned to (1) the exercise 
intervention or (2) usual medical care. The intervention 
arm will receive a 3-month, supervised and individually 
tailored modular multimodal exercise programme with 
spinal isometric training. Primary endpoints (feasibility 
and safety) and secondary endpoints (tumour morphology; 
biomarker activity; anthropometry; musculoskeletal 
health; adiposity; physical function; quality of life; anxiety; 
distress; fatigue; insomnia; physical activity levels) will 
be measured at baseline and following the intervention. 
Statistical analyses will include descriptive characteristics, 
t-tests, effect sizes and two-way (group × time) repeated-
measures analysis of variance (or analysis of covariance) 
to examine differences between groups over time. The 
data-set will be primarily examined using an intention-to-
treat approach with multiple imputations, followed by a 
secondary sensitivity analysis to ensure data robustness 
using a complete cases approach.
Ethics and dissemination Ethics approval was obtained 
from the Human Research Ethics Committee (HREC) of 
Edith Cowan University and the Sir Charles Gairdner and 
Osborne Park Health Care Group. If proven to be feasible 
and safe, this study will form the basis of future phase 
II and III trials in human patients with advanced cancer. 
To reach a maximum number of clinicians, practitioners, 
patients and scientists, outcomes will be disseminated 
through national and international clinical, conference 
and patient presentations, as well as publication in high-
impact, peer-reviewed academic journals.
Trial registration number ACTRN 12616000179437.
IntroductIon
Bone is the most common location for meta-
static prostate carcinoma, with skeletal lesions 
identified in >80% of patients with advanced 
prostate cancer.1–5 These lesions predomi-
nantly present as sclerotic (osteoblastic) and 
primarily reside in the axial skeleton (spine, 
Strengths and limitations of this study
 ► This is a novel, phase I randomised controlled trial in 
humans exploring the preliminary effects of targeted 
exercise on tumour morphology and circulating 
metastatic tumour biomarkers using a sclerotic 
skeletal metastases model in patients with prostate 
cancer.
 ► The study is principally aimed at establishing 
feasibility and safety, and may lack statistical power 
or a suitable length of intervention to determine 
the efficacy of exercise on tumour biology and 
metastatic tumour biomarkers.
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pelvis or ribs),6–8 presenting a considerable challenge 
for practitioners to deliver exercise interventions to this 
population.9 10 In particular, advanced cancer patients 
have historically been excluded from exercise interven-
tion studies and community-based supervised exercise 
programmes due to potential adverse skeletal events. 
Consequently, patients with advanced cancer often fail to 
receive the crucial benefits of exercise in the management 
of their disease; that is, to reduce treatment toxicities, 
delay disease progression and increase survival through 
neoadjuvant, adjuvant, synergistic and targeted appli-
cations. Clinically, bone metastases present as a major 
concern with patients experiencing severe bone pain, 
increased risk of skeletal complications, spinal compres-
sion, hypercalcaemia and decreased physical function 
and quality of life.9–13 Subsequently, patients with meta-
static bone disease experience significant morbidity with 
many barriers to exercise participation, thus strategies to 
safely and effectively reduce the burden of bone meta-
static disease have a high degree of clinical importance.
Despite the unequivocal benefits of exercise for 
patients with cancer,14–25 fear of adverse skeletal events 
has led to reduced uptake by patients, and reduced refer-
rals to exercise programmes by clinicians9 10 18; a cycle 
which exacerbates musculoskeletal fragility and tumour 
progression. In recent times, Galvão and colleagues9 10 21 
designed a modular, multimodal exercise programme 
(M3EP) to provide this population with safe and effec-
tive exercise modified to avoid direct loading of lesion 
sites; the first of its kind in exercise oncology. Preliminary 
findings have been promising, with exercise shown to 
be well tolerated (safe and efficacious), delivering clear 
improvements in physical function, physical activity levels 
and lean mass in these patients.10 21 However, it is not 
yet known whether direct loading of lesion sites in bone 
metastases is safe to deliver, or therapeutically advanta-
geous in providing adjuvant, synergistic or independent 
health benefits or tumorous modulations in patients with 
advanced prostate cancer.
Exercise positively alters tumour biology via numerous 
mechanisms in response to a variety of modes and 
dosages.26–33 Specifically, exercise regulates endo-
crine–paracrine activity, immune system function, 
blood glucose levels, blood cholesterol levels, insulin 
response and body composition34–41, while epigeneti-
cally modulating tumour cell proliferation, telomere 
length, telomere enzyme activity, tumour vascularity, 
oxidative stress capacity, platelet cloaking and platelet 
adhesion.26–33 42–47 Although these regulatory and modu-
latory outcomes interact, the ability to suppress tumour 
formation, growth and spread by virtue of altered 
epigenetics and endocrine–paracrine activity through 
exercise is of particular interest. This emerging field 
of mechanomics in exercise oncology (biological alter-
ations driven from biomechanical stimuli)48–51 presents 
practitioners with a unique opportunity to potentially 
suppress metastatic prostate carcinoma in bone through 
targeted exercise interventions.
Direct loading of animal metastatic bones containing 
human breast cancer tumour cells supports this 
new direction, successfully interfering with metasta-
sis-driven tumour formation50 by delivering suppressive 
localised modulatory changes to the tumour microenvi-
ronment, while preserving bone material, structure and 
strength.49 50 Given the impressive ability of mechanical 
loading to epigenetically interfere with metastasis-driven 
tumour formation in osteolytic tumour cells, it is of equal 
interest to determine whether mechanical loading is also 
able to alter metastasis-driven tumour formation in scle-
rotic tumour cells. This may also prove to be an effective 
adjuvant intervention to alleviate bone pain, preserve 
musculoskeletal strength and suppress sclerotic tumour 
expansion. To our knowledge, no studies have directly 
targeted skeletal metastases in advanced cancer patients 
through controlled, localised exercise programmes in 
order to plausibly modulate tumour biology and suppress 
tumour growth in humans; nor are we aware of any studies 
that have specifically established the feasibility or safety 
of loading skeletal sites with sclerotic bone metastases in 
patients with advanced prostate cancer.
The aim of this study is to (1) examine whether a 
modular multimodal exercise programme with spinal 
isometric training is feasible and safe in patients with 
advanced prostate cancer and sclerotic bone metastases 
in order to produce targeted and localised adaptations 
surrounding spinal lesions and (2) examine the prelim-
inary efficacy of targeted and supervised exercise to 
suppress sclerotic tumour growth and activity in spinal 
metastases in humans. We hypothesise that the exercise 
programme will be feasible and safe to deliver to patients 
with advanced prostate cancer; and that the exercise 
programme will help reduce the rate of sclerotic tumour 
progression. In addition, we also hypothesise the exer-
cise programme will alleviate bone pain; not increase 
the incidence of skeletal fractures; act to preserve muscle 
and bone; improve physical fitness and functional ability; 
reduce cancer-related fatigue and increase quality of life 
and psychosocial well-being. The outcomes of this trial 
will be used to improve clinical knowledge pertaining to 
exercise prescription for advanced cancer patients with 
metastatic prostate carcinoma, specifically promoting 
isometric loading of bones with sclerotic lesions. The 
outcomes of this trial will also be used to establish prelim-
inary efficacy of tumour suppression through exercise, 
thereby informing phase II and III clinical trials to help 




This is a single-blinded (investigators blinded to group 
allocation), two-armed, randomised and controlled (exer-
cise vs usual care) explorative phase I clinical trial which 
will examine the feasibility, safety and preliminary efficacy 
of combining spinal isometric training with a modulatory, 
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multimodal exercise programme (M3EP-SIT) in men 
with advanced prostate cancer and sclerotic spinal bone 
metastases. The exercise group (intervention arm) will 
receive an individually tailored and supervised 3-month 
(12 weeks) exercise programme involving resistance, 
aerobic, flexibility and isometric exercises in addition to 
usual medical care. The control group will receive usual 
medical care during this time and will be asked not to 
change their baseline levels of physical activity. Following 
the trial, the control group will be offered the same 
exercise programme if the intervention is deemed to be 
safe and feasible. This procedure has been shown to be 
an effective strategy to minimise study contamination, 
patient withdrawals or loss of patients to follow-up in 
prior exercise oncology trials.9 24 39
recruitment
Patients will be recruited by invitation of their cancer 
specialist (urologist, radiation oncologist or medical 
oncologist) who will provide clinically eligible patients 
with a study information sheet and refer these patients to 
a study coordinator. If patients are interested in partici-
pation, and their eligibility is confirmed, they will receive 
an informed consent document to read and sign in the 
presence of a study investigator and clinical research 
coordinator before undertaking baseline measurements 
prior to randomisation (figure 1).
randomisation
Patients will be randomly allocated in a ratio of 1:1 to 
the two study arms: exercise or usual care, stratified by 
age (≤70 years,>70 years) and time since completion of 
chemotherapy, radiotherapy to spinal metastases, or 
change in hormone therapy (<3 months, ≥3 months) for 
approximate balance between groups in order to miti-
gate confounding factors pertaining to variations due to 
ageing (ie, differences in physical function, sarcopenia, 
osteopenia and osteoporosis) and to account for varia-
tions in the treatment and washout effect of any recent 
completions of chemotherapy and radiotherapy, or 
changes in hormone therapy (ie, if progressed to second-
line antiandrogen agents). All patients will be required to 
be on androgen deprivation therapy (ADT) prior to, and 
during this study, as per standard of care for this patient 
population. A research officer with no patient contact 
will be responsible for randomisation of patients into 
either group by using a computer random assignment 
programme. Study investigators and exercise physiol-
ogists conducting testing procedures will be blinded to 
group allocation. Only exercise physiologists not in the 
research team will be permitted to deliver the exercise 
intervention to participants in order to maintain integrity 
of the blinding process.
Participants
Forty men (20 subjects per arm) with prostate cancer and 
stable bone metastases in cervical, thoracic and/or lumbar 
vertebrae, who have not engaged in regular exercise (ie, 
undertaking structured aerobic or resistance training two 
or more times per week) within the past three months will 
serve as participants. Due to the novelty of this explorative 
phase I clinical trial with a primary endpoint to establish 
feasibility and safety, our sample size was chosen based 
on prior preclinical animal studies,26 30 32 50 human pilot 
studies31 33 and consideration of recruitment ability for 
advanced prostate cancer patients with bone metastases. In 
addition, to demonstrate a meaningful difference (effect 
size ≥1.0; 80% power; alpha level of 0.05 (two-tailed)) for 
most secondary endpoints, 16 subjects per group would 
be required. To account for up to a 25% attrition rate, 
40 subjects will be randomised evenly to each study arm 
(exercise: n=20; control: n=20) to assist with establishing 
preliminary efficacy of secondary endpoints and to form 
the basis of sophisticated power calculations for future 
phase II and III randomised controlled trials.
Patients will be excluded from this trial if they have 
commenced chemotherapy, if they are receiving radio-
therapy for any spinal bone metastases, if they have 
commenced or changed hormone therapy within 3 
months of enrolment or are currently receiving any 
other experimental treatments or non-approved thera-
pies. Patients are permitted to receive radiotherapy for 
non-spinal bone metastases while enrolled in this trial. 
Patients require medical clearance prior to enrolment, 
therefore they must achieve an Eastern Cooperative 
Oncology Group performance status of ≤1; and must not 
Figure 1 Schematic overview of the study protocol. 
DXA, dual-energy X-ray absorptiometry; pQCT, peripheral 
quantitative CT; 1RM, one repetition maximum.
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have any acute illness, significant bone pain or cardio-
vascular or neurological disorders that could inhibit 
exercise participation. All participants must provide 
written informed consent prior to participation. The 
protocol has been approved by the Human Research 
Ethics Committee of Edith Cowan University (ID: 13 399 
HART and 14 146 HART); and Sir Charles Gairdner 
and Osborne Park Health Care Group (ID: 2016–118). 
This trial is also registered with the Australia and New 
Zealand Clinical Trails Register (ANZCTR), trial ID: 
ACTRN-12616000179437. All data relevant to the study 
will be kept on password-encrypted computers accessible 
by study investigators situated at the Exercise Medicine 
Research Institute (Perth, WA, Australia).
Measurements
Primary and secondary endpoints will be assessed at base-
line (week 0), postintervention (week 13) and throughout 
the 12-week on-trial period (table 1).
Primary endpoint
Feasibility
Feasibility will be quantified through a series of multi-
item categories including patient recruitment and 
trial completion; patient safety; programme tolerance; 
programme adherence and programme compliance 
(table 2). Programme safety will be assessed by recording 
the incidence and severity of adverse events and/or skel-
etal complications throughout the on-trial period for 
intervention and control arms. Skeletal complications 
include heightened pain at sites of bone metastases and/
or pathological skeletal fractures. The nature, severity 
and impact of bone pain will be examined using the 
FACIT Bone Pain questionnaire at baseline and post 
intervention.
Programme tolerance, adherence and compliance will 
be assessed for the intervention arm only. Specifically, 
programme tolerance will be quantified by measuring 
presessional bone pain and fatigue at each exercise 
session through visual analogue scales (VAS, 0–10) and 
by recording sessional rating of perceived exertion (Borg 
Scale, 0–10) and sessional tolerance (VAS, 0–7) after each 
exercise session.
Programme adherence and compliance will be assessed 
using an exercise diary completed by the patient at all 
clinic-based and home-based exercise sessions to record 
the volume of resistance training (weight lifted (kg), sets 
and repetitions), aerobic training (intensity (level), dura-
tion (minutes), speed (revolutions-per-minute), heart 
rate (maximum and average) and rating of perceived 
exertion) flexibility training (repetitions) and isometric 
training (repetitions and hold duration) completed. 
These data will be compared with the prescribed and indi-
vidualised exercise programme provided to each patient 
in order to establish programme adherence (completed 
vs missed sessions) and compliance (prescribed vs actual 
exercise completed for each training modality (resis-
tance, aerobic, flexibility and isometric)).
secondary endpoints
Tumour morphology
Tumour morphology will be measured using axial 
T1-weighted MRI scans (1.5T, Magnetom Essenza, 
Siemens, Victoria, Australia) in locations where sclerotic 
lesions have been identified in patients with bone metas-
tases at either thoracic or lumbar spinal regions.52–54 
Location of metastatic lesions will be previously recorded 
through bone scans provided by the patient’s primary 
oncologist prior to referral to this study. All scans will 
be performed on the same MRI machine by the same 
radiologist using a standardised sequence and routine 
for scout and primary acquisitions. Specifically, spinal 
bone metastases will be identified and confirmed using 
three preliminary axial scout scans in the sagittal plane 
to view cervical, thoracic and lumbar regions, respectively 
(T2-weighted; imaging frequency=63.66 Hz; slice thick-
ness=3.0–4.0 mm; spacing between slices=3.6–6.0 mm; 
echo train length=16–21; flip angle=140–150°; acquisition 
matrices=256\0\0\192 (cervical), 448\0\0\358 (thoracic), 
320\0\0\320 (lumbar)).
Primary acquisition for each affected vertebrae will be 
performed in the transverse plane, capturing the vertebrae 
above and below to produce an image with three verte-
brae in total (T1-weighted; imaging frequency=63.66 Hz; 
slice thickness=4.0 mm; space between slices=4.2 mm; 
echo train length=3; flip angle=150°; acquisition 
matrix=384\0\0\307). Following acquisition, tumour 
morphology (volume (mm3), intensity (W/sr) will be 
examined for each slice using ITK-Snap (V.3.6.0) image 
analysis software55 (figure 2). All images will be exam-
ined at the conclusion of the study by two independent 
researchers for consistency in analysis and to establish 
intra-rater and inter-rater reliability coefficients.
Biomarkers
Metastatic tumour biomarkers, hypoxia-inducible factor 
1-alpha (HIF-1α) and transformation growth-like factor 
beta (TGF-β) will be examined through unfasted serolog-
ical samples acquired at baseline and postintervention 
testing sessions to measure hypoxic activity and trans-
formation-growth activity, respectively; identified as key 
synergistic drivers of metastatic tumour progression.56 
Fasted serological and first-void urianalytical samples 
will be collected within 48 hours of baseline and postin-
tervention testing sessions to measure bone metabolic 
activity and systemic inflammation. Specifically, bone 
formation marker, amino-terminal propeptide of type 1 
procollagen (P1NP); bone resorption marker, aminoter-
minal collagen type I telopeptide (NTx); bone disorder 
marker, alkaline phosphate (ALP); inflammation marker, 
C reactive protein (CRP) and fasting glucose and lipid 
profiles will be examined. Prostate-specific antigen (PSA) 
will also be assessed. All fasted serological and first-void 
urianalytical biomarkers will be collected in the morning, 
and assessed by the same accredited laboratory (St John 
of God Hospital, Pathology Laboratory, Perth, Western 
Australia).
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Anthropometry
Stature will be recorded to the nearest 0.1 cm using a 
wall-mounted stadiometer (Model 222, Seca, Hamburg, 
DE), with body mass recorded to the nearest 0.1 kg 
using an electronic scale (AE Adams CPW Plus-200, 
Adam Equipment, CT, USA). Waist and hip circumfer-
ences are defined as the midpoint between the tenth rib 
and iliac crest; and the level of the greater trochanter, 
respectively, with the waist-to-hip ratio calculated. Waist 
circumference and hip circumference will be measured 
to the nearest 0.1 cm using a constant-tension, retract-
able measuring tape (Model 4414, Tech-Med Services, 
NY, USA). Stature, waist circumference and hip 
circumference will be performed in triplicate for each 
participant, with the average of each variable retained 
for analysis.
Table 1 Schedule of assessments at baseline and post intervention
Measures Baseline Post intervention
Tumour morphology (off-site)
  MRI scan: T1-axial X X
Tumour biomarkers
  Blood: HIF-1α, TGF-β X X
Anthropometry
  Height (cm) X
  Weight (kg) X X
  Waist circumference (cm) X X
  Hip circumference (cm) X X
  Femoral length (mm) X
  Tibial length (mm) X
  Body mass index (kg/m2) X X
  Waist-to-hip ratio X X
Body composition
  DXA scans: whole-body, spinal, hip X X
  pQCT scans: femoral, tibial X X
Physical assessments
  NeuroCom Balance test X X
  1RM Strength test (leg extension) X X
  400m walk test X X
  Timed Up and Go test X X
Other biomarkers (off-site)
  Blood: P1NP, ALP, CRP, fasting glucose and lipids, PSA X X
  Urine: NTx X X
Questionnaires
  Demographic and health history X
  Concomitant medications X X
  Health-related Quality of Life (SF-36) X X
  Cancer-specific Quality of Life (EORTC: QLQ30, PR25) X X
  Brief Symptom Index (BSI-18) X X
  Insomnia Severity Index X X
  Godin Leisure-Time Exercise X X
Exercise programme
  Clinic exercise record sheet (prescribed vs actual) At each exercise session
  Home exercise record sheet (prescribed vs actual) At each exercise session
ALP, alkaline phosphate; CRP, C reactive protein; DXA, dual-energy X-ray absorptiometry; EORTC, European Organisation for Research 
and Treatment of Cancer; HIF-1α, hypoxia-inducible factor 1-alpha; NTx, amino-terminal collagen type 1 telopeptide; P1NP, amino-
terminal propeptide of type 1 procollagen; pQCT, peripheral quantitative CT; PSA, prostate-specific antigen; SF-36, short form-36; TGF-β, 
transformation growth-like factor beta.
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Musculoskeletal health
Whole-body, segmental (axial, appendicular) and 
regional (spinal, hip, proximal femur) scans will be 
performed to examine bone area, areal bone mineral 
content, areal bone mineral density (aBMD) and lean 
mass using dual-energy X-ray absorptiometry (DXA; 
Hologic Discovery A, Waltham, MA). Whole-body and 
appendicular segmentations will be analysed in accor-
dance with Hart and colleagues.57 Regional analyses 
(lumbar spine, total hip, femoral neck, trochanter, Wards 
triangle) will be performed in accordance with Hologic’s 
manufacturer specifications.58
Appendicular, non-lesion control sites will be scanned 
to quantify bone material, structure and strength using 
peripheral Quantitative Computed Tomography (pQCT; 
XCT-3000, Stratec, Pzochienheim, Germany). Specifi-
cally trabecular, cortical, marrow and total volumetric 
density (Tb.vBMD, Ct.vBMD, Ma.vBMD, Tt.vBMD); 
trabecular, cortical, marrow and total cross-sectional area 
(Tb.Ar, Ct.Ar, Ma.Ar, Tt.Ar); cortical thickness (Ct.Th); 
stress–strain index (SSIPOL); absolute fracture load (FL.
Ab) and relative fracture load (FL.Rel) of the left femur 
(4% and 33% slices) and left tibia (4%, 14%, 38% and 
66% slices) will be measured and analysed in accordance 
with Hart and colleagues.59 Muscle cross-sectional area 
(Mu.Ar) will also be quantified.
Adiposity
Whole-body, segmental and central subcutaneous adipose 
tissue (fat mass), central visceral adipose tissue (VAT; 
area, mass and volume) and android to gynoid ratio 
will be measured using DXA. Whole-body and appen-
dicular segmentations will be generated in accordance 
with Hart and colleagues.57 Fat area (Fa.Ar) and muscle 
density (Mu.Den) of the thigh and shank segments will 
be measured using pQCT,59 as an indication of subcuta-
neous and intramuscular fat infiltration, respectively.
Objective measures of physical function
Muscle strength, aerobic capacity and physical function 
will be measured through a series of assessments. Muscle 
strength will be measured using the one repetition 
maximum (1RM) test for the leg extension exercise. This 
exercise was chosen as it can be safely performed by all 
patients included in this study. The 400m walk test and 
Timed Up and Go test will be used as measures for aerobic 
capacity and physical function respectively. In addition, 
patients will also undergo a comprehensive balance test 
(NeuroCom Smart Balance Master, Natus Medical, USA).
Quality of life, anxiety, distress, fatigue, insomnia and physical 
activity
Health-related quality-of-life outcomes for general 
health, pain, vitality, social functioning, emotional role 
and mental health will be measured by the Short Form 36 
(SF-36, IQOLA) survey. In addition, the EORTC QLQ-C30 
(cancer) and EORTC PR-25 (prostate cancer) surveys will 
also be provided to measure cancer-specific indices of 
quality of life. Specifically, the EORTC QLQ-C30 includes 
five functional scales (physical, role, emotional, cognitive 
and social functioning), three symptom scales (fatigue, 
nausea and vomiting, and pain), a global health/quali-
ty-of-life scale and six single items (dyspnoea, insomnia, 
appetite loss, constipation, diarrhoea and financial diffi-
culty); whereas the EORTC PR-25 also assesses urinary 
symptoms, bowel symptoms, treatment-related symptoms 
and sexual functioning. The FACIT fatigue questionnaire 
will be administered to directly assess cancer-related 
Table 2 Assessments of study feasibility
Measures Time of collection
Recruitment and completion
  Referred patients Trial completion
  Eligible patients Trial completion
  Enrolled patients Trial completion
  Eligibility rate Trial completion
  Recruitment rate Trial completion
  Trial completions Trial completion
  Patient withdrawals Trial completion
  Patient dropouts Trial completion
  Trial contamination Trial completion
Patient safety (control arm)
  Number of adverse events Tri-weekly record
  Severity of adverse events Tri-weekly record
  Number of skeletal complications Tri-weekly record
Patient safety (intervention arm)
  Number of adverse events
At each exercise 
session
  Severity of adverse events
At each exercise 
session
  Number of skeletal complications
At each exercise 
session
Programme tolerance (intervention arm)
  Presessional bone pain
At each exercise 
session
  Presessional fatigue
At each exercise 
session
  Sessional rating of perceived 
exertion
At each exercise 
session
  Sessional tolerance
At each exercise 
session
Programme adherence (intervention arm)
  Number of completed sessions Post intervention
  Number of missed sessions Post intervention
Programme compliance (intervention arm)
  Prescribed versus actual exercise 
completed (for each exercise mode) Post intervention
  Percent of total volume completed 
(for each exercise mode) Post intervention
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fatigue. The Brief Symptom Inventory (BSI-18) will be 
used to assess psychological distress for anxiety, depres-
sion, somatisation and global distress severity domains. 
The Insomnia Severity Index (ISI) will be used to measure 
sleep quality disturbance, and the Godin Leisure-Time 
Exercise questionnaire will examine self-reported phys-
ical activity levels.
exercise programme
Participants assigned to the exercise arm will be required 
to participate in a modular, multimodal exercise inter-
vention with spinal isometric training (M3EP-SIT) for 
12 weeks (3 months). The combined M3EP-SIT program 
requires participants to attend three clinic-based exercise 
sessions each week spanning 60 min in duration (including 
warm-up and cool-down), supervised by an accredited 
exercise physiologist (AEP; Exercise and Sport Science 
Australia) and autoregulated in collaboration with the 
patient (ie, adjusted based on the patient's presentation 
at each session). Participants will also be asked to perform 
the SIT program during two additional home-based exer-
cise sessions each week spanning approximately 15 min 
in duration from week 3 onwards to allow initial familia-
risation and competency assurance during the first two 
weeks. During the combined M3EP-SIT sessions, spinal 
isometric training will be provided first, followed by the 
modular multimodal exercise programme (table 3).
The M3EP component of the programme will be 
comprised of resistance, aerobic and flexibility exercises 
in accordance with Galvão and colleagues.9 This M3EP 
component is designed to minimise loads on affected 
Figure 2 Example MRI image acquisition. (Left) Cervical, thoracic and lumbar scout views stitched together with two 
sclerotic lesions identified at T8 and T11. (Top, middle) Thoracic scout view at higher resolution with the T11 vertebrae 
magnified. (Bottom, middle) Example data outputs provided by regional analysis. (Right) Slice by slice, cephalad to caudal, 
transverse view at each level of the T11 lesion, with an example colour map and tumoural analysis of one slice in isolation.
Table 3 Weekly distribution of testing, M3EP and SIT exercise sessions across the exercise intervention
 Monday  Tuesday  Wednesday  Thursday  Friday  Saturday  Sunday
Week 0 Baseline testing
Weeks 1–2 SIT M3EP – SIT M3EP – SIT M3EP REST REST
Weeks 3–12 SIT M3EP SIT SIT M3EP SIT SIT M3EP REST REST
Week 13 Post-intervention testing
Clinic exercise sessions occur on Monday, Wednesday and Friday; home isometric exercise sessions occur on Tuesday and Thursday. 
Spinal isometric exercises are provided at the start of all clinic exercise sessions (following a general warm-up). Home-based SIT start from 
week 3 onwards to enable appropriate familiarisation and training during the first two weeks of the programme. M3EP, multimodal exercise 
programme (60 min); SIT, spinal isometric training (15 min).
group.bmj.com on June 20, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Hart NH, et al. BMJ Open 2017;7:e014458. doi:10.1136/bmjopen-2016-014458
Open Access 
skeletal sites throughout the body. Exercise prescriptions 
will be modified based on the location and extent of bone 
metastases for all activities (table 4). Resistance exercise 
will be set using RM. Participants will be asked to perform 
six different resistance exercises using major muscle 
groups, subject to the location and extent of bone metas-
tases, at 8–12 RM for three sets per exercise to achieve 
moderate intensity and volume. Aerobic exercise will be 
set using age-predicted heart rate maximum (HRmax). 
Participants will undertake cardiovascular exercise using 
cycle ergometers, performing moderate-to-high-intensity 
(60–85% HRmax) interval training for a total duration of 
20 min, and monitored using heart rate monitors (Polar 
Electro Oy, Finland). Flexibility exercise will involve 
static stretching of all joints considered important for 
function and for all muscles engaged during the session. 
All stretches will involve 2–4 sets per muscle group with 
a 30–60 s hold per set. All resistance and aerobic exer-
cise prescriptions will be progressive and periodised in 
accordance with each patient’s individually determined 
physical capabilities and known contraindications.
The SIT component of the programme will comprise 
of exercises that isometrically load deep spinal muscles. 
These will be performed five times per week. Three 
sessions will be supervised by an AEP synonymous with 
the M3EP component at an exercise clinic; with an addi-
tional two sessions self-managed by the participant. This 
SIT component is designed to directly target and stimu-
late spinal lesion site(s) through muscular contraction, 
thus isometric exercises have been designed to activate 
the full spinal column due to the commonality of lesions 
in thoracic and lumbar regions; the feasibility of which 
has been demonstrated.60 The SIT program will require 
the participants to perform five exercises in whole and 
partial weight-supported prone and supine positions on 
the floor, while maintaining a neutral spine (isometri-
cally) during gentle and dynamic accessory movements. 
If floor exercises are contraindicated for the patient due 
to physical restrictions, alternate seated and standing 
isometric exercises are also provided. All patients will 
be initially provided with familiarisation of breathing 
technique, trunk stabilisation and hip control. Basic 
spinal isometric exercises will first be used to ensure safe 
and correct technique prior to progressing to interme-
diate or more challenging exercises which include less 
stability or dynamic accessory movements.61 Isometric 
progression of patients from beginner to advanced 
exercises will be individually determined on the basis of 
their physical capabilities and known contraindications. 
An assortment of spinal isometric exercises canvassing 
the beginner to advanced, floor to standing spectrum is 
described in online supplementary table 1, table 2, with 
an assortment of sample photographs provided in the 
online supplementary figure for prone and supine floor-
based exercises.
statistical analysis
Data will be analysed using SPSS (IBM, Chicago, IL, 
USA). Normality of distribution for continuous variables 
will be determined using the Kolmogorov-Smirnov test 
and visual inspection of the data. Analyses will include 
standard descriptive characteristics, t-tests and two-way 
(group × time) repeated-measures analysis of variance 
(or analysis of covariance as appropriate) to examine 
differences between groups over time. Any data that 
are not normally distributed will be log-transformed 
or non-parametric tests will be used. For categorical 
variables, Pearson's χ2 test will be used. An alpha level 
of p ≤0.05 will be applied to establish statistical signifi-
cance. Effect sizes will also be calculated in accordance 
with Hopkins62: d ≥0.2 is small; d ≥0.6 is moderate; 
d ≥1.2 is large; d ≥2.0 is very large. Incomplete data 
and missing values will be primarily managed using an 
intention-to-treat approach63 with multiple imputation, 
specifically using maximum likelihood imputation of 
missing values. To ensure the robustness of our find-
ings, a secondary sensitivity analysis64 will be conducted 
using a complete cases approach.
dissemination
Outcomes of this trial will be broadly disseminated through 
various communication channels to maximise the potential 
Table 4 Modular multimodal exercise programme for patients with bone metastases9 10
Resistance Aerobic Flexibility
Metastases site Upper Trunk Lower WB NWB Static
Pelvis √ √ √† √ √
Lumbar spine √ √ √ √‡
Thoracic spine/
ribs √* √ √ √ √‡
Proximal femur √ √ √† √ √
All regions √* √† √ √‡
*Exclusion of shoulder flexion/extension/abduction/adduction – inclusion of elbow flexion/extension.
†Exclusion of hip extension/flexion – inclusion of knee extension/flexion.
‡ Exclusion of spine/flexion/extension/rotation. 
√ Target exercise region.
NWB, non-weight bearing (eg, cycling); WB, weight bearing (eg, walking).
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for further research and development. If proven to be safe, 
feasible and efficacious, the outcomes will form the basis of 
future phase II and III clinical trials. To ensure a high level 
of delivery to clinicians, practitioners, patients and scientists, 
outcomes will be disseminated through national and inter-
national clinical, patient and conference presentations, as 
well as publication in high-impact, peer-reviewed journals. 
On completion of the trial and following publication of the 
primary manuscripts, data requests can be submitted to the 
study investigators at the Exercise Medicine Research Insti-
tute (Edith Cowan University, Perth, WA, Australia).
dIscussIon
Metastatic prostate carcinoma spreads to bone in >80% of 
advanced prostate cancer cases and is presently an incur-
able, yet treatable stage of the disease during palliation.1–8 
Consequently, these patients are provided with a suite of 
treatments that serve to manage pain and slow tumour 
progression, including ADT, radiotherapy and chemo-
therapy. While beneficial, these treatments produce an 
array of burdensome side effects leading to considerable 
morbidity. The effectiveness of exercise as an adjuvant 
therapy to minimise, manage and, in some cases, reverse 
the adversities of primary therapies has been demon-
strated.14–25 Exercise has also shown synergistic potential 
with primary treatments, subsequently improving their 
potency; for example, enhancing chemotherapy through 
increased tumour vascularity to enable greater cytotoxic 
delivery at tumour sites.26–31 However, the direct influ-
ence of exercise on tumour biology remains largely 
unknown, despite many hypothesised mechanical and 
non-mechanical mechanisms of action.26 65–70 To date, 
orthotopic animal models have provided compelling 
new insight into the ability of mechanical stimulation 
to interfere with tumour-driven remodelling in skeletal 
tissue containing human breast cancer cells.48–51 Given 
that exercise is a dose-dependent mechanical stimulant 
which can be safely prescribed to ]advanced prostate 
cancer patients with bone metastases,9 10 it is of interest 
to examine whether similar modulatory interference of 
tumour formation and growth is achievable in humans.
This study will evaluate the feasibility, safety and prelim-
inary efficacy of combining spinal isometric training with 
a modular, multimodal exercise programme to provide a 
non-invasive, low-cost, innovative and scalable therapy in 
the management of advanced prostate cancer. Specifically, 
this study will examine the modulatory potential of direct 
and targeted mechanical loading of sclerotic bone lesions 
through isometric exercise to deliver muscle contrac-
tile forces that may suppress localised tumour formation 
in spinal bone metastases, mediate systemic activity of 
metastatic biomarkers HIF-1α (local hypoxia) and TGF-β 
(tumour activity), reduce bone pain and preserve localised 
and surrounding musculoskeletal mass and structure. In 
addition, this study will also examine the multidimensional 
effects of exercise in advanced prostate cancer patients with 
bone metastases on muscle bone health, adiposity, physical 
fitness, functional capacity and psychosocial health. The 
outcomes of this study will provide innovative, new evidence 
that may be used to pursue larger phase II and III clin-
ical trials to determine the efficacy of exercise on tumour 
suppression or regression in patients with sclerotic bone 
metastases secondary to prostate cancer. The outcomes 
of this study may also stimulate research into osteolytic or 
mixed bone metastases models with other primary cancer 
diagnoses and may also inform the development of effective 
pharmaceuticals for treatment. Lastly, this study presents 
an exercise intervention that, if effective following larger 
randomised controlled trials, can inevitably be delivered in 
clinical and community settings by exercise physiologists.
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